Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(05)74656-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Olanzapine exposure disordered lipid metabolism, gut microbiota and behavior in zebrafish (Danio rerio).
Comp Biochem Physiol C Toxicol Pharmacol
January 2025
College of Fisheries, Henan Normal University, Xinxiang 453007, PR China; Engineering Technology Research Center of Henan Province for Aquatic Animal Cultivation, Henan Normal University, Xinxiang 453007, PR China. Electronic address:
Olanzapine (OLZ) is widely used in the treatment of schizophrenia, and its metabolic side effects have garnered significant attention in recent years. Despite this, the specific side effects of OLZ and the underlying mechanisms remain inadequately understood. To address this gap, zebrafish (Danio rerio) were exposed to OLZ at concentrations of 35.
View Article and Find Full Text PDFEffects of Age and Atomoxetine on Olfactory Perception and Learning and Underlying Plasticity Mechanisms in Rats.
Eur J Neurosci
January 2025
Biomedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
The locus coeruleus (LC) plays a vital role in cognitive function through norepinephrine release. Impaired LC neuronal health and function is linked to cognitive decline during ageing and Alzheimer's disease. This study investigates age-related alterations in olfactory detection and discrimination learning, along with its reversal, in Long-Evans rats, and examines the effects of atomoxetine (ATM), a norepinephrine uptake inhibitor, on these processes.
View Article and Find Full Text PDFMemantine-induced functional rewiring of the glutamate synapse in the striatum of dopamine transporter knockout rats.
Br J Pharmacol
December 2024
Department of Pharmacological and Biomolecular Sciences 'Rodolfo Paoletti', Università degli Studi di Milano, Milan, Italy.
Background And Purpose: Slow-acting biogenic amines, such as dopamine, are known to modulate fast neurotransmitters e.g. glutamate.
View Article and Find Full Text PDFCortical effects of dopamine replacement account for clinical response variability in Parkinson's disease.
medRxiv
November 2024
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Individual variability in clinical response to dopaminergic replacement therapy (DRT) is a key barrier to efficacious treatment for patients with Parkinson's disease (PD). A better understanding of the neurobiological sources of such inter-individual differences is necessary to inform future clinical interventions and motivate translational research. One potential source of this variability is an unintended secondary activation of extra-nigrostriatal dopamine systems by DRT, particularly in the neocortex.
View Article and Find Full Text PDFPresynaptic terminal integrity is associated with glucose metabolism in Parkinson's disease.
Eur J Nucl Med Mol Imaging
November 2024
Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Objective: To investigate the relationship of synaptic loss with glucose metabolism and dopaminergic transporters in Parkinson's disease (PD) patients.
Methods: A total of 16 patients with PD and 11 age-matched healthy controls underwent positron emission tomography (PET) with the tracers [F]SynVesT-1, a ligand for the presynaptic terminal marker synaptic vesicle protein 2 A (SV2A), and FDG. PD patients also underwent PET with the dopamine transporter (DAT) ligand [18F]FP-CIT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!